Table 2. Detection rates for BRCA1 and BRCA2 variants in breast/ovarian and male breast cancer families by Manchester score.
| Manchester score 50+ | Manchester score 40–49 | Manchester score 35–39 | Manchester score 30–34 | Manchester 25–29 | Total | |
|---|---|---|---|---|---|---|
| Breast/ovary | 44/51 (87%) | 46/60 (77%) | 38/53 (66%) | 40/87 (43%) | 44/146 (30%) | 212/397 (53%) |
| MBC | 5/5 (100%) | 5/8 (62.5%) | 7/12 (58%) | 8/13 (61.5%) | 2/16 (12.5%) | 27/54 (50%) |
| Total | 49/56 (87.5%) | 51/68 (75%) | 45/65 (69%) | 48/100 (48%) | 46/162 (28%) | 239/451 (53%) |
| RNA analysis in negative | 7/7 | 7/17 | 10/20 | 8/62 | 5/116 | 37/222 |
| RNA positive | 1/7 | 1/7 | 0/11 | 0/8 | 0/5 | 2/37 |
| Panel testing | 6/6 | 7/16 | 11/20 | 8/62 | 5/116 | 37/220 |
| Panel positive | 1x RAD51D of 6 | 0/7 | 1x ATM 1x CHEK2 of 11 | 0/8 | 0/5 (0/5 <25) | 3/42 |
| Female breast only | 4/5 (80%) | 11/19 (58%) | 21/37 (57%) | 34/69 (49%) | ||
| RNA FBC | 1 | 1 | 2 (4-16-20) | 0/8 | ||
| Panel testing | 0/1 | 0/1 | 0/1 (0/1 20) | 0/3 |
Abbreviations: FBC, female breast cancer; MBC, male breast cancer.